

**CLAIMS**

Claim 3 (Currently Amended) A monoclonal antibody that immunoreacts with lipopolysaccharide (LPS) binding protein (LBP), but does not substantially inhibit LBP binding to LPS, wherein said antibody has a binding specificity to LBP, to denatured LBP, and to a complex of LBP and LPS, and wherein said binding specificity is that of Mab 4D7, Mab 5C5, Mab 6B6, Mab 8C9, Mab 18G4, or Mab 24B7.

Claim 6 (Currently Amended) A monoclonal antibody that immunoreacts with lipopolysaccharide (LPS) binding protein (LBP), inhibits LBP-mediated binding of LPS to CD14, but does not substantially inhibit LBP binding to LPS, wherein said monoclonal antibody has a binding specificity to LBP, to denatured LBP, and to a complex containing LBP and LPS, and wherein said binding specificity is that of Mab 4D7, Mab 5C5, Mab 6B6, Mab 18G4, or Mab 24B7.

Claim 7 (Previously Presented) The monoclonal antibody of claim 6, wherein the monoclonal antibody inhibits LBP-mediated LPS-dependent activation of myeloid cells.

Claim 8 (Previously Presented) The monoclonal antibody of claim 6, wherein the monoclonal antibody inhibits LBP-mediated LPS-dependent secretion of tumor necrosis factor from myeloid cells.

Claim 12 (Currently Amended) A hybridoma cell line that produces a monoclonal antibody that immunoreacts with lipopolysaccharide (LPS) binding protein (LBP), inhibits LBP-mediated binding of LPS to CD14, but does not substantially inhibit LBP binding to LPS,

wherein said monoclonal antibody has a binding specificity to LBP, to denatured LBP, and to a complex containing LBP and LPS, and wherein said binding specificity is that of Mab 4D7, Mab 5C5, Mab 6B6, Mab 18G4, or Mab 24B7.

Claim 21. (Original) A pharmaceutical composition comprising at least one dose of an immunotherapeutically effective amount of the monoclonal antibody of claim 7 in a pharmacological carrier.

Claim 22. (Original) The pharmaceutical composition of claim 21 wherein said composition contains two or more different monoclonal antibodies.